MRKR Stock Discussion
Marker Therapeutics, Inc. Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Solid Tumors Immune System Immunotherapy Treatment Of Cancer Cancer Treatment Oncology Tumor Cancer Immunotherapy Cell Therapy Immunotherapies Virotherapy Ovarian Cancer Hematological Malignancies T Cell Her2 Her2/Neu Breast And Ovarian Cancer Tumor Cell Metastatic Disease
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Popular Now
Featured Articles